Aiboding (Cladribine) – HCL | HongKong DengYue Medicine

Aiboding Application Scope

Aiboding is the injectable form of cladribine, used as a targeted chemotherapy agent for Hairy Cell Leukemia.

Characteristics

• Ingredients: Cladribine

• Properties:

  • Clear, colorless, sterile, preservative-free, isotonic IV solution

  • pH ~5.5–8.0 (adjusted to ≈6.3)

  • Synthetic purine nucleoside analog; cytotoxic to lymphocytes and monocytes

• Packaging Specification: Single-use vials containing 10 mg cladribine in 10 mL solution

• Storage: Store refrigerated. Use aseptic technique; no preservatives

• Expiry Date: Meets USP monograph for cladribine injection (90–110% labeled dose)

• Executive Standard: U.S. FDA approval under the Accelerated Approval Program

• Approval Number: Refer to the national/region-specific marketing authorization.

• Date of Revision: Latest FDA label update: Jan 2025

• Manufacturer:

  • Marketed by Fresenius Kabi / Pfizer

  • Hisun under cladribine injection USP listings

Guidelines for the Use of Aiboding

• Dosage and Administration:

  • Standard regimen: continuous IV infusion 0.09 mg/kg/day for 7 days

  • Dilute with designated diluent; prepare aseptically

• Adverse Reactions:

  • Bone marrow suppression (thrombocytopenia, anemia, neutropenia)

  • High-dose associated toxicities: nephrotoxicity, neurological damage

  • Infusion-related effects: monitor renal and neurologic function

• Contraindications:

  • Known hypersensitivity to cladribine

  • Avoid in uncontrolled infections and severe bone marrow suppression

• Precautions:

  • Requires supervision by an experienced oncologist

  • Use aseptic technique; monitor CBC, renal, and liver function regularly

  • Monitor for neurologic symptoms and nephrotoxicity

Aiboding Interactions

• Drug Interactions:

  • Caution with other marrow-toxic or nephrotoxic drugs

  • Cladribine’s metabolism has not been extensively studied with transporters

  • Eliminated via renal and hepatic routes

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.